MDGL
MADRIGAL PHARMACEUTICALS, INC.
$501.19
+0.29%
$11.6B
No data for this timeframe.
Vol
Market Cap$11.6B
Cap SizeLarge Cap
Analyst ConsensusStrong Buy (87%)
Inst. Holders50 funds
Inst. Value$10.4B
Inst. Activity24 buys / 23 sells
Insider Activity0B / 9S
Insider Net $-$3.0M
SEC Reports6
Press Releases1
Recent Activity
Jun 4, 2026
other
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
<p>CONSHOHOCKEN, Pa., June 04, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MD
Jun 1, 2026
Insider
Soergel David sold 1,042 shares
Chief Medical Officer @ $495.74 ($516.6K)
May 22, 2026
SEC
Two Madrigal insiders (Director Levy and CMO Soergel) sold a combined $456K in open-market transactions, representing ap
CLUSTER — Impact 3/10
May 22, 2026
Insider
Levy Richard S sold 40 shares
Director @ $506.68 ($20.3K)
May 18, 2026
Insider
Soergel David sold 844 shares
Chief Medical Officer @ $515.90 ($435.4K)
May 6, 2026
SEC
Madrigal Pharmaceuticals reported Q1 2026 Rezdiffra net sales of $311.3M (+127% YoY), beating consensus revenue estimate
8-K — Impact 7/10
Apr 28, 2026
SEC
Madrigal Pharmaceuticals reclassified two directors (Julian Baker and Daniel Brennan) to Class I to balance board classe
8-K — Impact 2/10
Inst.
JANUS HENDERSON GROUP PLC — ADD
2,018,647 shares ($1.1B)
Price Targets
$678.71
+35.4% upside
Strong Buy
Current $501.19
Low $542.00
Median $649.50
High $964.00
14 analysts
$542.00
$964.00
Analyst Ratings
5Strong Buy
15Buy
3Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 11, 2026 | B of A Securities | MAINTAIN | Neutral → Neutral |
| May 13, 2026 | Truist Securities | MAINTAIN | Buy → Buy |
| May 7, 2026 | Canaccord Genuity | MAINTAIN | Buy → Buy |
| May 7, 2026 | Evercore ISI Group | MAINTAIN | Outperform → Outperform |
| May 6, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-2.23 ▼ -58.4% | $-2.38 — $-2.03 | -17% YoY | 3 |
| Next Q | $-1.03 ▼ -69.4% | $-1.42 — $-0.82 | 79% YoY | 3 |
| Current FY | $-6.52 ▼ -12.8% | $-7.11 — $-6.15 | 49% YoY | 3 |
| Next FY | $12.38 ▼ -3.2% | $10.01 — $16.78 | 290% YoY | 3 |
Latest Reports
NEUTRAL
CLUSTER
3/10
Two Madrigal insiders (Director Levy and CMO Soergel) sold a combined $456K in open-market transactions, representing ap
May 22, 2026
BULLISH
8-K
7/10
Madrigal Pharmaceuticals reported Q1 2026 Rezdiffra net sales of $311.3M (+127% YoY), beating consensus revenue estimate
May 6, 2026
NEUTRAL
Press
3/10
Madrigal Pharmaceuticals granted 1,739 restricted stock units to seven new non-executive employees as inducement awards
Mar 19, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| NOMURA ASSET MANAGEMENT CO | — | — |
| BAKER BROS. ADVISORS LP | $1.1B | — |
| JANUS HENDERSON GROUP PLC | $1.1B | ADD |
| RTW INVESTMENTS, LP | $1.0B | — |
| Avoro Capital Advisors LLC | $951.8M | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 1, 2026 | Soergel David | SELL | $516.6K |
| May 22, 2026 | Levy Richard | SELL | $20.3K |
| May 18, 2026 | Soergel David | SELL | $435.4K |
| Mar 6, 2026 | Sibold William | SELL | $718.3K |
| Mar 6, 2026 | Kelley Shannon | SELL | $155.5K |
50 institutional holders with $10.4B total value (19,788,900 shares) as of 2026-Q1. Top holders: NOMURA, BAKER, JANUS. Net buying activity: 24 institutions added/increased vs 23 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | NOMURA ASSET MANAGEMENT CO LTD | — | $0.00 | 0.0% | — |
| 2 | BAKER BROS. ADVISORS LP | 2,141,701 | $1.1B | 10.8% | — |
| 3 | JANUS HENDERSON GROUP PLC | 2,018,647 | $1.1B | 10.2% | ADD +27.4% |
| 4 | RTW INVESTMENTS, LP | 1,993,687 | $1.0B | 10.1% | — |
| 5 | Avoro Capital Advisors LLC | 1,818,181 | $951.8M | 9.2% | — |
| 6 | BlackRock, Inc. | 1,559,965 | $816.6M | 7.9% | — |
| 7 | PAULSON & CO. INC. | 1,392,188 | $728.8M | 7.0% | — |
| 8 | VANGUARD PORTFOLIO MANAGEMENT LLC | 841,145 | $440.3M | 4.3% | — |
| 9 | VANGUARD CAPITAL MANAGEMENT LLC | 827,144 | $433.0M | 4.2% | — |
| 10 | WELLINGTON MANAGEMENT GROUP LLP | 694,958 | $363.8M | 3.5% | ADD +50.6% |
| 11 | STATE STREET CORP | 609,525 | $319.1M | 3.1% | — |
| 12 | FMR LLC | 511,728 | $267.9M | 2.6% | — |
| 13 | CITADEL ADVISORS LLC | 453,843 | $237.6M | 2.3% | — |
| 14 | WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | 340,519 | $178.3M | 1.7% | — |
| 15 | Invesco Ltd. | 329,519 | $172.5M | 1.7% | — |
| 16 | Polar Capital Holdings Plc | 289,310 | $151.4M | 1.5% | — |
| 17 | GOLDMAN SACHS GROUP INC | 277,371 | $145.2M | 1.4% | — |
| 18 | Hood River Capital Management LLC | 249,511 | $130.6M | 1.3% | — |
| 19 | Point72 Asset Management, L.P. | 225,510 | $118.0M | 1.1% | ADD +78.4% |
| 20 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 216,720 | $113.4M | 1.1% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| JANUS HENDERSON GROUP PLC | ADD | 1,584,843 | 2,018,647 | +27.4% | $1.1B | 2026-Q1 |
| WELLINGTON MANAGEMENT GROUP LLP | ADD | 461,402 | 694,958 | +50.6% | $363.8M | 2026-Q1 |
| Point72 Asset Management, L.P. | ADD | 126,435 | 225,510 | +78.4% | $118.0M | 2026-Q1 |
| MORGAN STANLEY | ADD | 150,462 | 191,294 | +27.1% | $100.1M | 2026-Q1 |
| BANK OF AMERICA CORP /DE/ | TRIM | 416,025 | 189,527 | -54.4% | $99.2M | 2026-Q1 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | DOUBLED | 23,226 | 185,331 | +697.9% | $97.0M | 2026-Q1 |
| TORONTO DOMINION BANK | NEW | — | 130,460 | — | $68.3M | 2026-Q1 |
| AMERIPRISE FINANCIAL INC | DOUBLED | 29,287 | 98,181 | +235.2% | $51.4M | 2026-Q1 |
| DEUTSCHE BANK AG\ | TRIM | 192,109 | 98,067 | -49.0% | $51.3M | 2026-Q1 |
| ALKEON CAPITAL MANAGEMENT LLC | TRIM | 240,000 | 80,000 | -66.7% | $41.9M | 2026-Q1 |
| Nuveen, LLC | TRIM | 118,363 | 62,060 | -47.6% | $32.5M | 2026-Q1 |
| SCHRODER INVESTMENT MANAGEMENT GROUP | ADD | 29,051 | 39,852 | +37.2% | $20.1M | 2026-Q1 |
| Rockefeller Capital Management L.P. | ADD | 19,661 | 33,849 | +72.2% | $17.7M | 2026-Q1 |
| BNP Paribas Asset Management Holding S.A. | DOUBLED | 15,347 | 32,879 | +114.2% | $17.2M | 2026-Q1 |
| Connor, Clark & Lunn Investment Management Ltd. | TRIM | 58,295 | 27,937 | -52.1% | $14.6M | 2026-Q1 |
| Clearbridge Investments, LLC | NEW | — | 24,447 | — | $12.8M | 2026-Q1 |
| CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM | TRIM | 31,286 | 23,198 | -25.9% | $12.1M | 2026-Q1 |
| WCM INVESTMENT MANAGEMENT, LLC | ADD | 17,254 | 23,560 | +36.5% | $11.9M | 2026-Q1 |
| MARSHALL WACE, LLP | TRIM | 39,578 | 21,902 | -44.7% | $11.5M | 2026-Q1 |
| Assenagon Asset Management S.A. | DOUBLED | 5,390 | 16,033 | +197.5% | $8.4M | 2026-Q1 |
| HighTower Advisors, LLC | DOUBLED | 1,173 | 13,914 | +1086.2% | $7.3M | 2026-Q1 |
| STATE OF WISCONSIN INVESTMENT BOARD | ADD | 9,276 | 13,432 | +44.8% | $7.0M | 2026-Q1 |
| Neuberger Berman Group LLC | TRIM | 18,660 | 12,849 | -31.1% | $6.7M | 2026-Q1 |
| CANADA PENSION PLAN INVESTMENT BOARD | TRIM | 46,120 | 12,260 | -73.4% | $6.4M | 2026-Q1 |
| TUDOR INVESTMENT CORP ET AL | DOUBLED | 5,285 | 11,630 | +120.1% | $6.1M | 2026-Q1 |
7 unique insiders with 20 transactions. Net insider value: -$3.0M ($0.00 bought, $3.0M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 1, 2026 | Soergel David | Chief Medical Officer | SELL | 1,042 | $495.74 | $516.6K |
| May 22, 2026 | Levy Richard S | Director | SELL | 40 | $506.68 | $20.3K |
| May 18, 2026 | Soergel David | Chief Medical Officer | SELL | 844 | $515.90 | $435.4K |
| Mar 6, 2026 | Sibold William John | President and CEO | SELL | 1,663 | $431.94 | $718.3K |
| Mar 6, 2026 | Kelley Shannon T | General Counsel | SELL | 360 | $431.94 | $155.5K |
| Mar 6, 2026 | Dier Mardi | EVP and CFO | SELL | 646 | $431.94 | $279.0K |
| Mar 6, 2026 | Huntsman Carole | Chief Commercial Officer | SELL | 419 | $431.94 | $181.0K |
| Mar 6, 2026 | Taub Rebecca | Director | SELL | 491 | $431.94 | $212.1K |
| Mar 4, 2026 | Dier Mardi | EVP and CFO | AWARD | 6,519 | — | — |
| Mar 4, 2026 | Sibold William John | President and CEO | AWARD | 18,743 | — | — |
| Mar 4, 2026 | Huntsman Carole | Chief Commercial Officer | AWARD | 3,989 | — | — |
| Mar 4, 2026 | Huntsman Carole | Chief Commercial Officer | AWARD | 4,986 | — | — |
| Mar 4, 2026 | Dier Mardi | EVP and CFO | AWARD | 5,215 | — | — |
| Mar 4, 2026 | Sibold William John | President and CEO | AWARD | 14,995 | — | — |
| Mar 4, 2026 | Kelley Shannon T | General Counsel | AWARD | 4,017 | — | — |
| Mar 4, 2026 | Kelley Shannon T | General Counsel | AWARD | 5,022 | — | — |
| Mar 4, 2026 | Soergel David | Chief Medical Officer | AWARD | 4,374 | — | — |
| Mar 4, 2026 | Soergel David | Chief Medical Officer | AWARD | 5,467 | — | — |
| Mar 2, 2026 | Dier Mardi | EVP and CFO | SELL | 1,183 | $427.21 | $505.4K |
| Feb 23, 2026 | Levy Richard S | Director | EXERCISE | 2,500 | $7.36 | $18.4K |
6 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 0 mixed, 5 neutral. Avg impact: 3.7/10.
NEUTRAL
CLUSTER
3/10
Two Madrigal insiders (Director Levy and CMO Soergel) sold a combined $456K in open-market transacti
May 22, 2026
BULLISH
8-K
7/10
Madrigal Pharmaceuticals reported Q1 2026 Rezdiffra net sales of $311.3M (+127% YoY), beating consen
May 6, 2026
NEUTRAL
8-K
2/10
Madrigal Pharmaceuticals reclassified two directors (Julian Baker and Daniel Brennan) to Class I to
Apr 28, 2026
NEUTRAL
PRESS-RELEASE
3/10
Madrigal Pharmaceuticals announced it will release its Q1 2026 financial results on May 6, 2026. No
Apr 22, 2026
NEUTRAL
CLUSTER
4/10
Seven insiders at Madrigal Pharmaceuticals, including the CEO, CFO, and other C-suite executives, co
Mar 6, 2026
NEUTRAL
CLUSTER
3/10
Two Madrigal Pharmaceuticals insiders conducted open-market sales totaling $717K in the past week, i
Mar 6, 2026
Current analyst consensus: Strong Buy (87% buy). Based on 23 analysts: 5 strong buy, 15 buy, 3 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$678.71 mean target
+35.4% upside
Strong Buy (1.38)
$542.00 Low
$964.00 High
| Metric | Value |
|---|---|
| Current Price | $501.19 |
| Target Low | $542.00 |
| Target Mean | $678.71 |
| Target Median | $649.50 |
| Target High | $964.00 |
| # Analysts | 14 |
| Recommendation | Strong Buy (1.38) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-2.23 | $-2.38 | $-2.03 | -17.4% | -58.4% | 0↑ 1↓ | $0.3B | 64.3% | 3 |
| Next Q 2026-09-30 |
$-1.03 | $-1.42 | $-0.82 | 79.2% | -69.4% | — | $0.4B | 36.3% | 3 |
| Current FY 2026-12-31 |
$-6.52 | $-7.11 | $-6.15 | 48.7% | -12.8% | 1↑ 2↓ | $1.5B | 56.0% | 3 |
| Next FY 2027-12-31 |
$12.38 | $10.01 | $16.78 | 289.8% | -3.2% | 2↑ 1↓ | $2.2B | 47.5% | 3 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-2.230 | |
| 7d ago | $-2.230 | |
| 30d ago | $-1.408 | -0.822 |
| 60d ago | $-1.408 | -0.822 |
| 90d ago | $-1.438 | -0.792 |
8 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 11, 2026 | B of A Securities | MAINTAIN | Neutral | Neutral |
| May 13, 2026 | Truist Securities | MAINTAIN | Buy | Buy |
| May 7, 2026 | Canaccord Genuity | MAINTAIN | Buy | Buy |
| May 7, 2026 | Evercore ISI Group | MAINTAIN | Outperform | Outperform |
| May 6, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Feb 20, 2026 | B of A Securities | MAINTAIN | Neutral | Neutral |
| Jan 28, 2026 | Barclays | INITIATE | — | Overweight |
| Jan 20, 2026 | Citizens | MAINTAIN | Market Outperform | Market Outperform |
| Dec 19, 2025 | Piper Sandler | MAINTAIN | Overweight | Overweight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 5 | 15 | 3 | 0 | 0 | 87% | |
| May 1, 2026 | 5 | 15 | 3 | 0 | 0 | 87% | |
| Apr 1, 2026 | 5 | 15 | 3 | 0 | 0 | 87% | |
| Mar 1, 2026 | 5 | 15 | 3 | 0 | 0 | 87% | |
| Feb 1, 2026 | 5 | 16 | 3 | 0 | 0 | 88% | |
| Jan 1, 2026 | 6 | 15 | 2 | 0 | 0 | 91% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 4, 2026
other
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
<p>CONSHOHOCKEN, Pa., June 04, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delive
Jun 4, 2026
Clinical Trial
Study of MGL-3196 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)
Phase Phase 2 — COMPLETED
May 6, 2026
earnings
Madrigal Pharmaceuticals Reports First-Quarter 2026 Financial Results and Provides Corporate Updates
<p>CONSHOHOCKEN, Pa., May 06, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL), a biopharmaceutical company focused on deliver
May 6, 2026
earnings_calendar
MDGL Q1 2026 Earnings Before Market Open — 2026-05-06
Apr 22, 2026
earnings
Madrigal Pharmaceuticals to Release First-Quarter 2026 Financial Results and Host Webcast on May 6, 2026
<p>CONSHOHOCKEN, Pa., April 22, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its firs
Apr 21, 2026
other
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
<p>CONSHOHOCKEN, Pa., April 21, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delive
Apr 7, 2026
other
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
<p>CONSHOHOCKEN, Pa., April 07, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delive
Apr 7, 2026
short_interest
FTD: MDGL — 4,628 shares ($2.5M) failed to deliver
Settlement: 20260407, Price: $533.88, FTD Value: $2,470,796.64, MADRIGAL PHARMACEUTICALS INC C
Mar 26, 2026
short_volume
Short Volume: MDGL — 60.5% short (0.3M / 0.5M)
Short: 319,168 | Exempt: 1,293 | TRF Vol: 527,766 | Short Ratio: 60.5% | Off-exchange volume (dark pool + OTC)
Mar 19, 2026
activist
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
<p align="left">CONSHOHOCKEN, Pa., March 19, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focu
Mar 5, 2026
other
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
<p>CONSHOHOCKEN, Pa., March 05, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delive
Feb 20, 2026
short_interest
FTD: MDGL — 2,898 shares ($1.3M) failed to deliver
Settlement: 20260220, Price: $436.87, FTD Value: $1,266,049.26, MADRIGAL PHARMACEUTICALS INC C
Feb 2, 2026
short_interest
FTD: MDGL — 1,133 shares ($0.6M) failed to deliver
Settlement: 20260202, Price: $489.31, FTD Value: $554,388.23, MADRIGAL PHARMACEUTICALS INC C